Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned.

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) has limited treatment options, with few drugs approved in recent decades.
• Type 1 interferons (IFN) are consistently found to be activated in most SLE patients and play a pathogenic role.
• Previous drug development for SLE has not adequately addressed unmet clinical needs.

Purpose of the Study:

• To review the development and efficacy of type 1 interferon (IFN)-targeting therapies for systemic lupus erythematosus (SLE).
• To highlight the challenges and successes in targeting the type 1 IFN pathway in SLE drug discovery.
• To discuss the future implications of IFN-targeting therapies in SLE treatment.

Main Methods:

• Review of clinical trial data for therapies targeting the type 1 IFN pathway in SLE.
• Analysis of the efficacy and safety of anifrolumab, a monoclonal antibody targeting the type I IFN receptor.
• Examination of ongoing research into other IFN-targeting strategies, including cellular and small molecule approaches.

Main Results:

• Anifrolumab demonstrated efficacy in a Phase III trial, leading to its approval for SLE treatment in multiple regions.
• While initial IFN-targeting agents showed promise, blocking the type I IFN receptor proved more successful.
• Subsequent Phase II trials for other IFN-pathway inhibitors, including TYK2 inhibitors, have yielded positive results.

Conclusions:

• Targeting the type 1 IFN pathway represents a significant advancement in SLE treatment.
• Despite complexities in SLE clinical trials, IFN-targeting therapies are established and expanding.
• The development of IFN-targeting drugs offers valuable lessons for future SLE therapeutic strategies.